Adjuvant Pembrolizumab in Patients with Stage IIIA/N2 Non-Small Cell Lung Cancer Completely Resected after Neoadjuvant Concurrent Chemoradiation: A Prospective, Open-Label, Single-Arm, Phase 2 Trial

CONCLUSION: Adjuvant pembrolizumab may offer durable disease control in a subset of stage IIIA/N2 NSCLC patients after neoadjuvant CCRT and surgery.PMID:38697848 | DOI:10.4143/crt.2024.084

https://pubmed.ncbi.nlm.nih.gov/38697848/?utm_source=no_user_agent&utm_medium=rs...

Source: Cell Research - May 2, 2024 Category: Cytology Authors: Junghoon Shin Sehhoon Park Kyung Hwan Kim Eui-Cheol Shin Hyun Ae Jung Jong Ho Cho Jong-Mu Sun Se-Hoon Lee Yong Soo Choi Jin Seok Ahn Jhingook Kim Keunchil Park Young Mog Shim Hong Kwan Kim Jae Myoung Noh Yong Chan Ahn Hongryull Pyo Myung-Ju Ahn Source Type: research